Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal EU

HOME

Work Package 6

Improving interoperability among industrial biotechnology operators

WP6 will focus on the various steps of the DBTL (design, build, test, learn) cycle and simultaneously demonstrate the capacity of the IBISBA 1.0 network to perform collaborative work in a framework of standardised and shared protocols and harmonised procedures. To achieve this a multi-partner task force, including early stage postdoctoral researchers will be assembled to perform DBTL cycles on target host strains. At the design step, tools specific for strain design (e.g. genome-wide multi-pathway models and pathway prediction tools) will be deployed alongside flowsheet/process modelling, thus providing early integration of industrial constraints and decisionmaking features. In the build step, a range of technical operations (e.g. DNA synthesis, assembly and genome engineering using for example CRISPR-Cas9) will be used, employing or developing standard operating protocols (SOPs) that will form part of the network shared assets. Moreover, at this stage focus will be given to microtiter scale high-throughput screening, to identify robust performance markers. In the Test phase scale-up issues will be tackled, notably focused on the challenge of moving from microtiter scale highthroughput cultivation and analytical methods will be deployed to assess performance of hundreds or thousands of strains. This stage does not allow well controlled culture conditions, neither a broad range of analytics. Consequently the challenges lie on one hand on how to measure in a predictable manner the desired outcome of the strain design, and on the other that right strains will be selected, which would also perform as designed in controlled bioreactors, and have predicted process adaptability to larger production scales.

WP Leader: Dr. Merja Penttilä (F), VTT - Finland
merja.pentilla@vtt.fi 

WP Co-Leader: Dr. Jussi Jäntti (M), VTT - Finland
jussi.jantti@vtt.fi